Skip to main content

ImmunityBio, Inc.

IBRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001326110

In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 3 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in ImmunityBio, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
116
No complete 13F data for Q4 2020
Shares held
16.0M
No complete 13F data for Q4 2020
Total value
$378.9M
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting IBRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 116 institutions
Q1 2021: 116 institutionsQ2 2021: 118 institutionsQ3 2021: 121 institutionsQ4 2021: 141 institutionsQ1 2022: 149 institutionsQ2 2022: 132 institutionsQ3 2022: 126 institutionsQ4 2022: 140 institutionsQ1 2023: 147 institutionsQ2 2023: 118 institutionsQ3 2023: 132 institutionsQ4 2023: 148 institutionsQ1 2024: 166 institutionsQ2 2024: 194 institutionsQ3 2024: 182 institutionsQ4 2024: 202 institutionsQ1 2025: 211 institutionsQ2 2025: 242 institutionsQ3 2025: 264 institutionsQ4 2025: 278 institutionsQ1 2026: 386 institutionsQ2 2026: 405 institutions
Value heldQ1 2021: $378.9M
Q1 2021: $378.9MQ2 2021: $390.1MQ3 2021: $310.9MQ4 2021: $209.7MQ1 2022: $199.8MQ2 2022: $123.1MQ3 2022: $196.3MQ4 2022: $256.0MQ1 2023: $84.1MQ2 2023: $108.7MQ3 2023: $84.1MQ4 2023: $288.9MQ1 2024: $356.9MQ2 2024: $391.1MQ3 2024: $255.6MQ4 2024: $211.8MQ1 2025: $239.4MQ2 2025: $327.9MQ3 2025: $352.1MQ4 2025: $338.3MQ1 2026: $1.36BQ2 2026: $1.76B
Institutions holding IBRX and their total value by quarter
QuarterHoldersValue
Q2 2026405$1.76B
Q1 2026386$1.36B
Q4 2025278$338.3M
Q3 2025264$352.1M
Q2 2025242$327.9M
Q1 2025211$239.4M
Q4 2024202$211.8M
Q3 2024182$255.6M
Q2 2024194$391.1M
Q1 2024166$356.9M
Q4 2023148$288.9M
Q3 2023132$84.1M
Q2 2023118$108.7M
Q1 2023147$84.1M
Q4 2022140$256.0M
Q3 2022126$196.3M
Q2 2022132$123.1M
Q1 2022149$199.8M
Q4 2021141$209.7M
Q3 2021121$310.9M
Q2 2021118$390.1M
Q1 2021116$378.9M

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding ImmunityBio, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding IBRX in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Bank of New York Mellon Corp166,847$3.96M0.00%––
Citigroup Inc170,248$4.04M0.00%––
Credit Suisse AG182,070$4.32M0.00%––
Price T Rowe Associates Inc202,938$4.82M0.00%––
Charles Schwab Investment Management Inc257,228$6.11M0.00%––
First Trust Advisors LP310,920$7.38M0.01%––
Morgan Stanley333,075$7.91M0.00%––
HarbourVest Partners LLC347,009$8.24M1.10%––
Susquehanna International Group, LLP470,227$11.2M0.01%––
Northern Trust Corp481,807$11.4M0.00%––
Rafferty Asset Management, LLC525,284$12.5M0.09%––
JPMorgan Chase & Co543,699$12.9M0.00%––
Geode Capital Management, LLC664,549$15.8M0.00%––
State Street Corp2,332,572$55.4M0.00%––
Vanguard Group Inc2,559,391$60.8M0.00%––
BlackRock Inc.3,553,665$84.4M0.00%––